Prentiss Smith & Co’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.59M | Sell |
2,060
-3
| -0.1% | -$2.3K | 0.92% | 31 |
|
|
2025
Q4 | $1.59M | Sell |
2,063
-13
| -0.6% | -$8.83K | 0.95% | 29 |
|
|
2025
Q3 | $1.17M | Sell |
2,076
-13
| -0.6% | -$7.35K | 0.66% | 36 |
|
|
2025
Q2 | $1.1M | Sell |
2,089
-21
| -1% | -$11.7K | 0.65% | 38 |
|
|
2025
Q1 | $1.34M | Buy |
2,110
+75
| +4% | +$51.6K | 0.87% | 33 |
|
|
2024
Q4 | $1.45M | Sell |
2,035
-2
| -0.1% | -$1.68K | 0.95% | 31 |
|
|
2024
Q3 | $2.14M | Sell |
2,037
-56
| -3% | -$62.3K | 1.37% | 27 |
|
|
2024
Q2 | $2.2M | Sell |
2,093
-1,452
| -41% | -$1.41M | 1.53% | 24 |
|
|
2024
Q1 | $3.41M | Sell |
3,545
-111
| -3% | -$106K | 2.4% | 19 |
|
|
2023
Q4 | $3.21M | Sell |
3,656
-1,779
| -33% | -$1.47M | 2.39% | 18 |
|
|
2023
Q3 | $4.47M | Sell |
5,435
-153
| -3% | -$120K | 3.3% | 12 |
|
|
2023
Q2 | $4.02M | Sell |
5,588
-17
| -0.3% | -$13.1K | 3.01% | 15 |
|
|
2023
Q1 | $4.61M | Sell |
5,605
-66
| -1% | -$49.8K | 3.42% | 10 |
|
|
2022
Q4 | $4.09M | Sell |
5,671
-228
| -4% | -$168K | 3.71% | 11 |
|
|
2022
Q3 | $4.06M | Sell |
5,899
-148
| -2% | -$93.2K | 3.61% | 9 |
|
|
2022
Q2 | $3.58M | Sell |
6,047
-129
| -2% | -$83.9K | 2.76% | 15 |
|
|
2022
Q1 | $4.31M | Sell |
6,176
-5,634
| -48% | -$3.56M | 2.59% | 16 |
|
|
2021
Q4 | $7.46M | Buy |
11,810
+327
| +3% | +$201K | 3.52% | 7 |
|
|
2021
Q3 | $6.95M | Sell |
11,483
-10
| -0.1% | -$6.21K | 3.53% | 6 |
|
|
2021
Q2 | $6.42M | Sell |
11,493
-251
| -2% | -$127K | 3.09% | 9 |
|
|
2021
Q1 | $5.56M | Buy |
11,744
+4,916
| +72% | +$2.39M | 2.86% | 14 |
|
|
2020
Q4 | $3.3M | Sell |
6,828
-904
| -12% | -$488K | 1.57% | 28 |
|
|
2020
Q3 | $4.33M | Sell |
7,732
-142
| -2% | -$86.1K | 2.26% | 21 |
|
|
2020
Q2 | $4.91M | Buy |
7,874
+6
| +0.1% | +$3.41K | 3.03% | 15 |
|
|
2020
Q1 | $3.84M | Sell |
7,868
-8,229
| -51% | -$3.39M | 2.67% | 17 |
|
|
2019
Q4 | $6.04M | Sell |
16,097
-395
| -2% | -$133K | 3.88% | 9 |
|
|
2019
Q3 | $4.58M | Buy |
16,492
+62
| +0.4% | +$18.3K | 3.07% | 16 |
|
|
2019
Q2 | $5.14M | Buy |
+16,430
| New | +$5.47M | 3.36% | 13 |
|
|
2019
Q1 | – | Sell |
-6,951
| Closed | -$2.6M | – | 63 |
|
|
2018
Q4 | $2.6M | Buy |
6,951
+77
| +1% | +$28.2K | 1.63% | 24 |
|
|
2018
Q3 | $2.78M | Sell |
6,874
-4,494
| -40% | -$1.71M | 1.58% | 21 |
|
|
2018
Q2 | $3.92M | Sell |
11,368
-8,385
| -42% | -$2.62M | 2.37% | 19 |
|
|
2018
Q1 | $6.8M | Buy |
19,753
+7,057
| +56% | +$2.45M | 3.57% | 11 |
|
|
2017
Q4 | $4.77M | Buy |
12,696
+11,765
| +1,264% | +$4.76M | 2.33% | 17 |
|
|
2017
Q3 | $416K | Buy |
+931
| New | +$443K | 0.24% | 50 |
|
|
2017
Q2 | – | Sell |
-751
| Closed | -$291K | – | 256 |
|
|
2017
Q1 | $291K | Buy |
751
+91
| +14% | +$33.7K | 0.17% | 61 |
|
|
2016
Q4 | $242K | Buy |
660
+485
| +277% | +$184K | 0.15% | 58 |
|
|
2016
Q3 | $70K | Hold |
175
| – | – | 0.04% | 104 |
|
|
2016
Q2 | $61K | Hold |
175
| – | – | 0.03% | 110 |
|
|
2016
Q1 | $63K | Hold |
175
| – | – | 0.04% | 110 |
|
|
2015
Q4 | $95K | Hold |
175
| – | – | 0.05% | 97 |
|
|
2015
Q3 | $81K | Hold |
175
| – | – | 0.04% | 101 |
|
|
2015
Q2 | $89K | Hold |
175
| – | – | 0.04% | 95 |
|
|
2015
Q1 | $79K | Hold |
175
| – | – | 0.04% | 105 |
|
|
2014
Q4 | $72K | Buy |
+175
| New | +$68.8K | 0.03% | 118 |
|
Other funds holding REGN
VCM
N
Prentiss Smith & Co's REGN Position: Q1 2026 in Review
Prentiss Smith & Co reduced its Regeneron Pharmaceuticals (REGN) stake by 0.15% in Q1 2026, selling an estimated $2.3K and leaving 2,060 shares worth $1.59M. The position accounts for 0.92% of the portfolio, ranked #31.
Prentiss Smith & Co first reported a position in REGN in Q4 2014 and has held it in 44 quarters since. The position peaked at $7.46M in Q4 2021. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Prentiss Smith & Co held 2,060 shares of Regeneron Pharmaceuticals worth $1.59M as of Q1 2026.
- Prentiss Smith & Co sold 3 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $2.3K.
- Regeneron Pharmaceuticals made up 0.92% of Prentiss Smith & Co's portfolio in Q1 2026, its #31 holding.
- Prentiss Smith & Co first reported a position in Regeneron Pharmaceuticals in Q4 2014 and has held it in 44 quarters since.
- Prentiss Smith & Co's Regeneron Pharmaceuticals position peaked at $7.46M in Q4 2021.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Prentiss Smith & Co's 13F filing for Q1 2026, filed 7 May 2026.